Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations
Completed
Orion Corporation, Orion Pharma
Phase 2
2011-05-01
The primary objective of the study is to assess the efficacy, carbidopa dose response and
safety of ODM-101, a new combination of levodopa, carbidopa and entacapone in the treatment
of Parkinson's disease (PD) patients with end-of-dose motor fluctuations.
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
Completed
Orion Corporation, Orion Pharma
Phase 3
2004-09-01
The CELC200A2401 study has been designed in order to evaluate the hypothesis that
administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy
is initiated results in a decrease in the risk of the development of motor complications for
patients with Parkinson's disease.
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
Completed
Novartis Pharmaceuticals
Phase 3
2004-09-01
The CELC200A2401 study has been designed in order to evaluate the hypothesis that
administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy
is initiated results in a decrease in the risk of the development of motor complications for
patients with Parkinson's disease.
A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
Completed
Novartis
Phase 3
2005-08-01
The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone
in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy
in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit
than immediate release carbidopa/levodopa administered at the same levodopa dosage level of
100 mg three times a day (t.i.d.).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
